Sarilumab

CHEMBL2108730 Phase 4 Одобрено Antibody

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

Given by injection under the skin, this biological medication blocks a protein called interleukin-6 that drives joint inflammation in rheumatoid arthritis. It is used when other disease-modifying drugs have not worked well enough, helping to reduce joint pain, swelling, and long-term joint damage.

Терапевтические области

Immunology Rheumatoid Arthritis Rheumatology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Часто задаваемые вопросы

Given by injection under the skin, this biological medication blocks a protein called interleukin-6 that drives joint inflammation in rheumatoid arthritis. It is used when other disease-modifying drugs have not worked well enough, helping to reduce joint pain, swelling, and long-term joint damage.

Yes, Sarilumab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108730. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Ищете информацию, доступную для пациентов?

Sarilumab на PillFYI

Краткие Данные

Синонимы: 1

Внешние ссылки

ChEMBL CHEMBL2108730

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Медицинский отказ от ответственности

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.